English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 13 January 2023, 15:06 JST
Share:
    

Source: Eisai
Eisai Launches Renewed Sustainability Page

TOKYO, Jan 13, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced that it has renewed the Sustainability page of its corporate website and it is now accessible to the public.


Sustainability Top Page
www.eisai.com/sustainability/index.html

The Eisai's Corporate Concept is "to give first thought to patients and the people in the daily living domain, and to increase the benefits that health care provides to them". Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. For realizing our corporate concept, it is necessary to implement corporate measures based on a long-term perspective under a well-cultivated governance structure. Therefore, it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues.

In order to provide information about our sustainability approach and activities in an easy-to-understand manner, we have enhanced the content, and renewed the key visuals, design and page structure. We have also featured our approach, targets and initiatives for improving access to medicines, which Eisai is focusing on, as well as the areas of environment, society and governance.

Through further efforts in our proactive disclosure of information for sustainability, we will aim to develop and maintain favorable relations with all of our stakeholders.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Monday, 26 January 2026, 11:37 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
2026年1月26日 8時40分 JST
エーザイとバイオジェン、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」について、早期アルツハイマー病に対する初期療法からの投与を可能とする生物製剤承認一部変更申請が米国 FDA に受理され、優先審査に指定
Wednesday, 21 January 2026, 16:44 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Tuesday, 13 January 2026, 9:50 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Tuesday, 6 January 2026, 10:43 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575